Laurus Labs Ltd. (LAURUSLABS) Share Price Hits Fresh 52-Week High

Laurus Labs Ltd. Share Price reached a fresh 52-week high of Rs 1,837.5, with a current price of Rs 1,821.05, marking a 0.27% increase today. The market cap stands at Rs 98,126.1 crore.

Laurus Labs Ltd. Share Price has reached a fresh 52-week high of Rs 1,837.5 today. Currently trading at Rs 1,821.05, the stock has experienced a modest increase of 0.27% from its previous close of Rs 1,816.1. With a market capitalisation of Rs 98,126.1 crore, Laurus Labs Ltd. is attracting significant attention in the market. The stock opened at Rs 1,820 and has seen a day low of Rs 1,788.75, indicating a volatile trading session. The turnover for the day is Rs 14.22 crore, with a volume of 78,089 shares traded. This fresh 52-week high highlights the stock's upward momentum and positions it as a key player in the healthcare sector.

Laurus Labs Ltd. Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,821.05
Previous Close	Rs 1,816.1
Today's Change	+Rs 4.95 (+0.27%)
Day Open	Rs 1,820
Fresh 52-Week High	Rs 1,837.5
Day Low	Rs 1,788.75
Current Volume	78,089
Turnover	Rs 14.22 crore
Market Capitalisation	Rs 98,126.1 crore

Laurus Labs Ltd. (LAURUSLABS) traded at Rs 1,821.05. versus the previous close of Rs 1,816.1, a rise of 0.27%. The stock opened at Rs 1,820, reached Rs 1,837.5, touched Rs 1,788.75. Reported volume was 78,089.

Today, Laurus Labs Ltd. Share Price opened at Rs 1,820 and reached a fresh 52-week high of Rs 1,837.5. The stock's current price is Rs 1,821.05, reflecting a 0.27% increase from the previous close of Rs 1,816.1. The day's low was Rs 1,788.75, indicating some volatility. With a turnover of Rs 14.22 crore and a volume of 78,089 shares, the stock has shown active participation. This price action suggests a strong interest in Laurus Labs Ltd., setting the stage for further analysis of its fundamentals and sector context.

Laurus Labs Ltd. (LAURUSLABS) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 98,126.1 crore
P/E Ratio	30.09x
P/B Ratio	0.44x
ROE	-2.89%
ROCE	-0.26%

Laurus Labs Ltd. was valued at a P/E ratio of 30.09x, a P/B ratio of 0.44x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of -2.89% and ROCE of -0.26%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Benchmark Scope	same sector
Company P/E Ratio	30.09x
Benchmark Median P/E	20.73x
Benchmark Average P/E	67.98x
Benchmark P/E Range	0x to 3,417.8x
Company P/B Ratio	0.44x
Benchmark Median P/B	1.91x
Company ROE	-2.89%
Benchmark Median ROE	10.7%
Company ROCE	-0.26%
Benchmark Median ROCE	13.13%
Company Market Capitalisation	Rs 98,126.1 crore
Benchmark Median Market Cap	Rs 130.49 crore

Laurus Labs Ltd. (LAURUSLABS) is classified under sector: Healthcare.

Laurus Labs Ltd. (LAURUSLABS) has a P/E ratio of 30.09x, which is above the benchmark median of 20.73x, a difference of +45.15%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Laurus Labs Ltd. (LAURUSLABS) has a ROE of -2.89%, which is below the benchmark median of 10.7%, a difference of -127.01%. Laurus Labs Ltd. (LAURUSLABS) has a ROCE of -0.26%, which is below the benchmark median of 13.13%, a difference of -101.98%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,931.84	30.09	0.44	-2.89	-0.26
Kwality Pharmaceuticals Ltd.	KPL	2,683.28	39.84	8.11	28.21	26.35
Beta Drugs Ltd.	BETA	2,474.26	59.65	7.97	18.65	22.17
Sai Parenteral's Ltd.	SAIPARENT	2,416.82	169.49	3.13	13.9	12.97
Dr Agarwals Eye Hospital Ltd.	DRAGARWQ	2,414	34.44	6.97	-2.6	16.92

Laurus Labs Ltd. (LAURUSLABS) has a P/E ratio of 30.09x compared with the displayed peer median of 39.84x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -2.89% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at -0.26% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. Laurus Labs Ltd. (LAURUSLABS) has a market capitalisation of Rs 98,126.1 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

Why Investors Are Watching Laurus Labs Ltd.

• Fresh 52-week high at Rs 1,837.5, indicating strong price momentum.
• Market cap of Rs 98,126.1 crore, highlighting significant market presence.
• Higher P/E ratio than sector median, suggesting premium valuation.
• Low P/B ratio compared to sector, indicating potential undervaluation.
• Negative ROE and ROCE, raising concerns about profitability.

About Laurus Labs Ltd.

Laurus Labs Ltd. is a prominent player in the healthcare sector, focusing on the development and manufacturing of active pharmaceutical ingredients (APIs), formulations, and custom synthesis. With a diverse product portfolio, the company serves various therapeutic areas, including anti-retrovirals, oncology, and cardiovascular. Laurus Labs Ltd. is committed to innovation and quality, leveraging its state-of-the-art manufacturing facilities and research capabilities to meet global healthcare needs. As a key player in the industry, the company continues to expand its market presence and enhance its product offerings.

Track Laurus Labs Ltd. Share Price on Univest

Use Laurus Labs Ltd. (LAURUSLABS) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.

Investors can track Laurus Labs Ltd. Share Price, technical indicators, fundamental ratios, shareholding pattern, 52-week levels, and market insights on Univest. Stay informed about the latest developments and make data-driven investment decisions.

Frequently Asked Questions

What is the current share price of Laurus Labs Ltd.?

Ans. The current share price of Laurus Labs Ltd. is Rs 1,821.05, reflecting a 0.27% increase from the previous close of Rs 1,816.1. The stock moved 0.27% during the session. The intraday range extended from Rs 1,788.75 to Rs 1,837.5.

What is the 52-week high of Laurus Labs Ltd.?

Ans. Laurus Labs Ltd. has reached a fresh 52-week high of Rs 1,837.5, indicating strong price momentum in the market. The stock moved 0.27% during the session. The intraday range extended from Rs 1,788.75 to Rs 1,837.5.

How does Laurus Labs Ltd.'s P/E ratio compare to the sector?

Ans. Laurus Labs Ltd.'s P/E ratio is 30.09, which is higher than the sector median of 20.73, indicating a premium valuation. The company trades at a P/E ratio of 30.09x. Its P/B ratio is 0.44x.

What is Laurus Labs Ltd.'s market capitalisation?

Ans. Laurus Labs Ltd. has a market capitalisation of Rs 98,126.1 crore, highlighting its significant presence in the healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 30.09x.

How does Laurus Labs Ltd.'s P/B ratio compare to the sector?

Ans. Laurus Labs Ltd.'s P/B ratio is 0.44, significantly lower than the sector median of 1.91, suggesting potential undervaluation. The company trades at a P/E ratio of 30.09x. Its P/B ratio is 0.44x.

What are Laurus Labs Ltd.'s ROE and ROCE?

Ans. Laurus Labs Ltd. has a negative ROE of -2.89% and ROCE of -0.26%, indicating challenges in profitability and capital efficiency. ROE stands at -2.89%. ROCE stands at -0.26%. The relevant peer median ROE is 10.7%.

Who are Laurus Labs Ltd.'s peers?

Ans. Laurus Labs Ltd.'s peers include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., Beta Drugs Ltd., Sai Parenteral's Ltd., and Dr Agarwals Eye Hospital Ltd. Comparable listed companies include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., Beta Drugs Ltd.

How does Laurus Labs Ltd.'s market cap compare to its peers?

Ans. Laurus Labs Ltd. has a market cap of Rs 98,126.1 crore, significantly higher than peers like Dishman Carbogen Amcis Ltd. and Kwality Pharmaceuticals Ltd. The company operates in the Healthcare sector.